Aquestive Therapeutics, Inc. Earnings Per Share (Diluted)
Aquestive Therapeutics, Inc. (AQST) reported Earnings Per Share (Diluted) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- Aquestive Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.18.
- Aquestive Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.07.
- Aquestive Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.26.
- Aquestive Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.14.
- Aquestive Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$0.78.
- Aquestive Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$0.51.
- Aquestive Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$0.13.
- Aquestive Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$1.12.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-11 | -$0.25 10-Q · filed 2026-08-11 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.07 10-Q · filed 2026-05-13 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.47 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.78 10-K · filed 2026-03-04 |
| 2025-09-30 | -$0.14 10-Q · filed 2025-11-05 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.51 10-Q · filed 2025-11-05 | -$0.70 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.14 10-Q · filed 2026-08-11 | -$0.37 10-Q · filed 2026-08-11 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.69 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.24 10-Q · filed 2026-05-13 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2024-12-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.51 10-K · filed 2026-03-04 |
| 2024-09-30 | -$0.13 10-Q · filed 2025-11-05 | -$0.16 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$0.32 10-Q · filed 2025-11-05 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-06-30 | -$0.03 10-Q · filed 2025-08-11 | -$0.19 10-Q · filed 2025-08-11 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2024-03-31 | -$0.17 10-Q · filed 2025-05-12 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-04-24 |
| 2023-12-31 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-04-24 | -$0.13 10-K · filed 2025-03-05 |
| 2023-09-30 | -$0.03 10-Q · filed 2024-11-04 | -$0.13 derived: net income ÷ weighted average shares · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | -$0.19 derived: net income ÷ weighted average shares · filed 2024-11-04 |
| 2023-06-30 | -$0.10 10-Q · filed 2024-08-06 | $0.04 10-Q · filed 2024-08-06 | -$0.16 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-11-04 |
| 2023-03-31 | $0.11 10-Q · filed 2024-05-07 | -$0.07 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$0.28 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$0.58 derived: net income ÷ weighted average shares · filed 2024-11-04 |
| 2022-12-31 | -$0.23 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.81 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$1.12 10-K · filed 2024-03-05 |
| 2022-09-30 | -$0.23 10-Q · filed 2023-11-06 | -$0.58 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$0.90 10-Q · filed 2023-11-06 | -$1.57 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2022-06-30 | -$0.36 10-Q · filed 2023-08-07 | -$0.68 10-Q · filed 2023-08-07 | -$1.38 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.75 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2022-03-31 | -$0.32 10-Q · filed 2023-05-02 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.41 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.75 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2021-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.09 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.44 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$1.85 10-K · filed 2023-03-31 |
| 2021-09-30 | -$0.37 10-Q · filed 2022-11-01 | -$0.71 derived: net income ÷ weighted average shares · filed 2022-11-01 | -$1.12 10-Q · filed 2022-11-01 | -$1.70 derived: net income ÷ weighted average shares · filed 2022-11-01 |
| 2021-06-30 | -$0.33 10-Q · filed 2022-08-02 | -$0.74 10-Q · filed 2022-08-02 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-11-01 | -$1.83 derived: net income ÷ weighted average shares · filed 2022-11-01 |
| 2021-03-31 | -$0.41 10-Q · filed 2022-05-04 | -$1.01 derived: net income ÷ weighted average shares · filed 2022-11-01 | -$1.50 derived: net income ÷ weighted average shares · filed 2022-11-01 | |
| 2020-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2022-03-08 | -$1.09 derived: net income ÷ weighted average shares · filed 2022-03-08 | -$1.66 10-K · filed 2022-03-08 | |
| 2020-09-30 | -$0.49 10-Q · filed 2021-11-02 | -$1.05 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | -$0.07 10-Q · filed 2021-08-03 | -$0.56 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | -$0.49 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |